



**For further information please contact:**

**Cellzome Inc**

Charles Cohen, Chairman

Tel: +49-6221-137 57-100

**Hogarth PR**

Melanie Toyne-Sewell / John Olsen

Tel: +44 (0) 207 357 9477

## Press release

### Tim Edwards joins Cellzome as CEO

**Boston, USA, 20 September, 2004** – Cellzome Inc, the proteomics and drug discovery company with laboratories in Heidelberg, Germany and Cambridge, England announced today that Tim Edwards has been appointed as Chief Executive Officer. He will take over from David Brown.

Tim Edwards, aged 47, was working as an advisor to Cellzome for the 7 months prior to being appointed as its Chief Operating Officer on 1 July 2004. Previously he held various senior positions at British Biotech plc, from 1997-2003, including COO and Acting Chief Executive. Before that, he was a Director of Corporate Finance at NatWest Markets (part of the NatWest Group plc) specialising in the healthcare sector. Tim is currently a non-executive director of ReOx Limited, a biotech company spun out of the University of Oxford.

David Brown, the outgoing Chief Executive, is retiring and will pursue other interests. The Board of Cellzome thanks David for his contribution to the company and wishes him well in the future.

#### **About Cellzome Inc.**

Cellzome is a drug discovery company building an R&D pipeline in chronic diseases. Cellzome is leveraging its powerful drug proteomics engine to generate a pipeline of drug development candidates, both for in-house drug development and through partnership. Cellzome's drug proteomics engine combines two proprietary methodologies, 'chemical proteomics', in which pharmacologically active compounds are used to affinity-capture their protein targets, and 'pathway expansion', which allows the elucidation of the proteins involved in molecular pathways. Cellzome's drug discovery focuses on the interface between validated disease pathways, tractable medicinal chemistry and 'druggable' targets.

Founded at the European Molecular Biology Laboratory (EMBL) in May 2000, Cellzome has combined scientific leadership with experienced pharmaceutical management. The company currently has approx. 90 employees with offices in Heidelberg, Germany and Cambridge, UK. Recent research collaborations have included partnerships with Bayer, Johnson & Johnson and Novartis (announced today). Cellzome is continuing to build its in-house drug discovery capabilities. To learn more about Cellzome visit [www.cellzome.com](http://www.cellzome.com)